Limits...
Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?

Shabani P, Naeimi Khaledi H, Beigy M, Emamgholipour S, Parvaz E, Poustchi H, Doosti M - PLoS ONE (2015)

Bottom Line: Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001).Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD.Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. Plasma concentration of CTRP1 was measured with ELISA method. Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001). Moreover, we observed significant positive correlations between plasma level of CTRP1 and fasting blood glucose (FBG) (p<0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (p<0.001), body mass index (BMI) (p = 0.001), alanine amino transferase (ALT) (p = 0.002), gamma glutamyl transferase (γ-GT) (p<0.001) and liver stiffness (LS) (p<0.001). Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD. Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.

No MeSH data available.


Related in: MedlinePlus

ROC curves for CTRP1, HOMA-IR, FBG, and liver stiffness are represented for a) NAFLD; b) T2DM; and c) NAFLD+T2DM patients.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4358971&req=5

pone.0118650.g003: ROC curves for CTRP1, HOMA-IR, FBG, and liver stiffness are represented for a) NAFLD; b) T2DM; and c) NAFLD+T2DM patients.

Mentions: The receiver operating characteristic (ROC) curves for NAFLD, T2DM, and NAFLD+T2DM regarding CTRP1, HOMA-IR, FBG, and LS are displayed in Fig. 3. Area under the curve (AUC) of CTRP1 (95% CI; p-value) was 0.355 (0.228–0.482; p = 0.061) for NAFLD (without T2DM) (Fig. 3a), 0.747 (0.637–0.857; p = 0.002) for T2DM (Fig. 3b), and 0.931 (0.871–0.991; p<0.001) for NAFLD +T2DM (Fig. 3c). CTRP1 did not provide a perfect sensitivity or specificity to differentiate NAFLD patients; thus we defined combinatory criteria to improve it. Actually, CTRP1≥350 ng/ml along with FBG<110 mg/dl could specifically differentiate NAFLD patients, with excellent diagnostic power (sensitivity = 90.91%; specificity = 100%; positive predictive value (PPV) for NAFLD without diabetes = 90.91%; negative present value (NPV) = 91.3%). But CTRP1 could not distinguish NAFLD from NAFLD+T2DM patients.


Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?

Shabani P, Naeimi Khaledi H, Beigy M, Emamgholipour S, Parvaz E, Poustchi H, Doosti M - PLoS ONE (2015)

ROC curves for CTRP1, HOMA-IR, FBG, and liver stiffness are represented for a) NAFLD; b) T2DM; and c) NAFLD+T2DM patients.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4358971&req=5

pone.0118650.g003: ROC curves for CTRP1, HOMA-IR, FBG, and liver stiffness are represented for a) NAFLD; b) T2DM; and c) NAFLD+T2DM patients.
Mentions: The receiver operating characteristic (ROC) curves for NAFLD, T2DM, and NAFLD+T2DM regarding CTRP1, HOMA-IR, FBG, and LS are displayed in Fig. 3. Area under the curve (AUC) of CTRP1 (95% CI; p-value) was 0.355 (0.228–0.482; p = 0.061) for NAFLD (without T2DM) (Fig. 3a), 0.747 (0.637–0.857; p = 0.002) for T2DM (Fig. 3b), and 0.931 (0.871–0.991; p<0.001) for NAFLD +T2DM (Fig. 3c). CTRP1 did not provide a perfect sensitivity or specificity to differentiate NAFLD patients; thus we defined combinatory criteria to improve it. Actually, CTRP1≥350 ng/ml along with FBG<110 mg/dl could specifically differentiate NAFLD patients, with excellent diagnostic power (sensitivity = 90.91%; specificity = 100%; positive predictive value (PPV) for NAFLD without diabetes = 90.91%; negative present value (NPV) = 91.3%). But CTRP1 could not distinguish NAFLD from NAFLD+T2DM patients.

Bottom Line: Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001).Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD.Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.

View Article: PubMed Central - PubMed

Affiliation: Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. Plasma concentration of CTRP1 was measured with ELISA method. Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001). Moreover, we observed significant positive correlations between plasma level of CTRP1 and fasting blood glucose (FBG) (p<0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (p<0.001), body mass index (BMI) (p = 0.001), alanine amino transferase (ALT) (p = 0.002), gamma glutamyl transferase (γ-GT) (p<0.001) and liver stiffness (LS) (p<0.001). Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD. Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.

No MeSH data available.


Related in: MedlinePlus